These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 20925691)

  • 1. In silico exploration for identifying structure-activity relationship of MEK inhibition and oral bioavailability for isothiazole derivatives.
    Melagraki G; Afantitis A; Sarimveis H; Igglessi-Markopoulou O; Koutentis PA; Kollias G
    Chem Biol Drug Des; 2010 Nov; 76(5):397-406. PubMed ID: 20925691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D-QSAR and molecular docking studies on substituted isothiazole analogs as inhibitors against MEK-1 kinase.
    Reddy BM; Tanneeru K; Meetei PA; Guruprasad L
    Chem Biol Drug Des; 2012 Jan; 79(1):84-91. PubMed ID: 21967481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel, selective and potent Chk2 inhibitors.
    Larson G; Yan S; Chen H; Rong F; Hong Z; Wu JZ
    Bioorg Med Chem Lett; 2007 Jan; 17(1):172-5. PubMed ID: 17035018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validated quantitative structure-activity relationship analysis of a series of 2-aminothiazole based p56(Lck) inhibitors.
    Li J; Du J; Xi L; Liu H; Yao X; Liu M
    Anal Chim Acta; 2009 Jan; 631(1):29-39. PubMed ID: 19046675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond the MEK-pocket: can current MEK kinase inhibitors be utilized to synthesize novel type III NCKIs? Does the MEK-pocket exist in kinases other than MEK?
    Tecle H; Shao J; Li Y; Kothe M; Kazmirski S; Penzotti J; Ding YH; Ohren J; Moshinsky D; Coli R; Jhawar N; Bora E; Jacques-O'Hagan S; Wu J
    Bioorg Med Chem Lett; 2009 Jan; 19(1):226-9. PubMed ID: 19019675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of EBI-1051: A novel and orally efficacious MEK inhibitor with benzofuran scaffold.
    Lu B; Huang S; Cao J; Hu Q; Shen R; Wan H; Wang D; Yuan J; Zhang L; Zhang J; Zhang M; Tao W; Zhang L
    Bioorg Med Chem; 2018 Feb; 26(3):581-589. PubMed ID: 29317148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QSAR modeling of the inhibition of glycogen synthase kinase-3.
    Katritzky AR; Pacureanu LM; Dobchev DA; Fara DC; Duchowicz PR; Karelson M
    Bioorg Med Chem; 2006 Jul; 14(14):4987-5002. PubMed ID: 16650999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo.
    Luke RW; Ballard P; Buttar D; Campbell L; Curwen J; Emery SC; Griffen AM; Hassall L; Hayter BR; Jones CD; McCoull W; Mellor M; Swain ML; Tucker JA
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6670-4. PubMed ID: 19854647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docking, 3D-QSAR studies and in silico ADME prediction on c-Src tyrosine kinase inhibitors.
    Tintori C; Magnani M; Schenone S; Botta M
    Eur J Med Chem; 2009 Mar; 44(3):990-1000. PubMed ID: 18722033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
    Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
    J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.
    Fidanze SD; Erickson SA; Wang GT; Mantei R; Clark RF; Sorensen BK; Bamaung NY; Kovar P; Johnson EF; Swinger KK; Stewart KD; Zhang Q; Tucker LA; Pappano WN; Wilsbacher JL; Wang J; Sheppard GS; Bell RL; Davidsen SK; Hubbard RD
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2452-5. PubMed ID: 20346655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors.
    Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK
    Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors.
    Dai Y; Hartandi K; Soni NB; Pease LJ; Reuter DR; Olson AM; Osterling DJ; Doktor SZ; Albert DH; Bouska JJ; Glaser KB; Marcotte PA; Stewart KD; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2008 Jan; 18(1):386-90. PubMed ID: 18023347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives.
    Ono K; Banno H; Okaniwa M; Hirayama T; Iwamura N; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
    Bioorg Med Chem; 2017 Apr; 25(8):2336-2350. PubMed ID: 28302507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR.
    Angell RM; Angell TD; Bamborough P; Brown D; Brown M; Buckton JB; Cockerill SG; Edwards CD; Jones KL; Longstaff T; Smee PA; Smith KJ; Somers DO; Walker AL; Willson M
    Bioorg Med Chem Lett; 2008 Jan; 18(1):324-8. PubMed ID: 17981461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors.
    Wallace MB; Adams ME; Kanouni T; Mol CD; Dougan DR; Feher VA; O'Connell SM; Shi L; Halkowycz P; Dong Q
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4156-8. PubMed ID: 20621728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of multivariate image analysis applied to quantitative structure-activity relationship (QSAR) analysis by using wavelet-principal component analysis ranking variable selection and least-squares support vector machine regression: QSAR study of checkpoint kinase WEE1 inhibitors.
    Cormanich RA; Goodarzi M; Freitas MP
    Chem Biol Drug Des; 2009 Feb; 73(2):244-52. PubMed ID: 19207427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploration of a binding mode of benzothiazol-2-yl acetonitrile pyrimidine core based derivatives as potent c-Jun N-terminal kinase-3 inhibitors and 3D-QSAR analyses.
    Sharma P; Ghoshal N
    J Chem Inf Model; 2006; 46(4):1763-74. PubMed ID: 16859308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel isothiazole inhibitors of the TrkA kinase: structure-activity relationship, computer modeling, optimization, and identification of highly potent antagonists.
    Lippa B; Morris J; Corbett M; Kwan TA; Noe MC; Snow SL; Gant TG; Mangiaracina M; Coffey HA; Foster B; Knauth EA; Wessel MD
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3444-8. PubMed ID: 16632359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.